Navigation Links
Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
Date:1/12/2009

ing his presentation, Mr. Watkins will discuss the following goals and updates on progress.

LATE-STAGE PRODUCTS

Albuferon(R): Met Primary Endpoint in Phase 3 Trial in Genotypes 2 and 3 Chronic Hepatitis C; Phase 3 Results in Genotype 1 Patients Expected March 2009

In December 2008, HGS reported that the results of ACHIEVE 2/3 demonstrated that Albuferon (albinterferon alfa-2b) met its primary endpoint of non-inferiority to peginterferon alfa-2a (Pegasys) in this global Phase 3 trial in 933 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C (p=0.0086). The data showed that the rate of sustained virologic response was comparable for the 900-mcg dose of Albuferon administered every two weeks, vs. the standard 180-mcg dose of peginterferon alfa-2a administered once weekly. Rates of serious adverse events, severe adverse events and discontinuations due to adverse events were also comparable. The results of ACHIEVE 1, the Phase 3 trial of Albuferon in genotype 1 chronic hepatitis C, are expected in March 2009. Albuferon is being developed by HGS and Novartis under an exclusive worldwide co-development and commercialization agreement entered into in June 2006.

"The data from ACHIEVE 2/3 show that the efficacy of Albuferon was comparable to Pegasys, with half the injections," said Mr. Watkins. "If Albuferon is also successful in ACHIEVE 1, we expect that global marketing applications will be filed in fall 2009 - and we believe Albuferon could become the market-leading interferon for the treatment of chronic hepatitis C,"

In a separate press release issued this morning, HGS announced that Novartis has initiated a Phase 2b trial to evaluate the safety and efficacy of Albuferon dosed monthly in treatment-naive patients with genotypes 2 and 3 chronic hepatitis C.

Key goals for Albuferon in 2009:

  • Report
    '/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 24, 2014 /CNW/ -   ... recalled after Health Canada tests confirmed it contains two ... (beta-methylphenethylamine and phenylpropylmethylamine). The distributor, Empire Health Distribution of ... product from retail stores across Canada ... including for weight loss and increased energy. ...
(Date:12/24/2014)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... preliminary financial results for the first quarter of ... Ended September 30, 2014 Financial Highlights: , ... in 1Q14 with gross margins improved to 52% ...
(Date:12/24/2014)... 2014  Conkwest, Inc., the Natural Killer Cell ... Killer (NK) cell-line platform, Neukoplast® (NK-92™) as an ... , NantWorks founder, physician scientist and biotechnology entrepreneur, ... approximately $48 million of the Company,s Class A ... will be named Co-Chairman of the Conkwest Board ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5
(Date:12/26/2014)... 26, 2014 DW-InductionHeating.com (DaWei Induction Heating ... researching and developing, producing and marketing of a series ... business announces their new series of induction brazing ... the company, induction brazing refers to the ... filler material and heat. The manager says that there ...
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 ... Market Analysis to 2023” focuses on the current ... opportunities in the colorectal cancer market. Stivarga is ... of colon or rectal cancer. Boehringer Ingelheim is ... for the treatment of refractory CRC in the ...
(Date:12/25/2014)... December 26, 2014 Recently, Dylan Queen, ... has excitedly released its collection of discounted prom dresses, ... Percy, a senior spokesman of the company, the promotion ... this promotion is to expand the UK market. , ... several different colors, lengths, and styles: A-line strapless, empire ...
(Date:12/25/2014)... When head lice hits a home or ... to get rid of it while keeping it from taking ... now have the solution right in their neighborhood: Lice ... Troopers provides full spectrum head lice screening and treatment services ... Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest and South ...
(Date:12/25/2014)... 2014 (HealthDay News) -- Among early stage breast cancer ... half of one percent will eventually develop leukemia as ... The finding comes from a review of more ... 2007, and it suggests that the risk for developing ... had previously thought. "The frequency of bone marrow ...
Breaking Medicine News(10 mins):Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... muscular atrophy , , THURSDAY, Jan. 10 (HealthDay News) -- ... pregnant with her second child. Her baby didn,t move, except ... leaving her stomach flat. , Her fears were confirmed ... weak cry, very little muscle tone, he had contractures in ...
... A protein found in human hair shows promise for ... a new treatment option when nerves are cut or crushed ... scientists from Wake Forest University School of Medicine reported that ... up nerve regeneration and improve nerve function compared to current ...
... federal, state levels to combat tobacco use, report says ... registered some significant gains in 2007, with more states ... too little federal and state funding for smoking-prevention and ... taxes. , That,s the conclusion of the American Lung ...
... Supported SelfCare,Inc., a national provider of disease ... awarded Full Disease Management Accreditation from URAC, ... establishes,quality standards for the healthcare industry., ... very seriously. This,national accreditation validates LifeMasters, clinical ...
... efforts through Consumer Innovation ... ... (NYSE:,WLP) is accepting applications for its first Consumer Innovation Event. The,event ... identifying and piloting innovative,programs and services., "The health benefits industry ...
... Jan. 9 Synergy Life Science,Partners, LP, a ... medical device technologies, today announced the successful,completion of ... of $143,million in committed capital. The firm has ... 2006 by John Onopchenko, Richard Stack, M.D., and ...
Cached Medicine News:Health News:Years-Long Search Unlocks Deadly Genetic Disease 2Health News:Years-Long Search Unlocks Deadly Genetic Disease 3Health News:Years-Long Search Unlocks Deadly Genetic Disease 4Health News:Protein in human hair shows promise for regenerating nerves 2Health News:Protein in human hair shows promise for regenerating nerves 3Health News:Smoke-Free Workplace Laws, Cigarette Taxes on the Rise 2Health News:Smoke-Free Workplace Laws, Cigarette Taxes on the Rise 3Health News:Smoke-Free Workplace Laws, Cigarette Taxes on the Rise 4Health News:LifeMasters Receives Full URAC Disease Management Accreditation 2Health News:LifeMasters Receives Full URAC Disease Management Accreditation 3Health News:WellPoint Announces Consumer Innovation Opportunity 2Health News:WellPoint Announces Consumer Innovation Opportunity 3Health News:Synergy Life Science Partners Closes $143M Debut Medical Device Fund 2Health News:Synergy Life Science Partners Closes $143M Debut Medical Device Fund 3
Revised Drug calibrator that replaces existing Drug calibrator - this product contains Lithium in addition to Digoxin, Phenobarbital, OPhenytoin, & Theophulline....
The Emit 2000 Digoxin Calibrators are intended for use with the Emit 2000 Digoxin Assay....
Liquichek Rheumatoid Factor Control is a liquid trilevel control designed to monitor rheumatoid factor testing procedures, including nephelometric and latex agglutination methods....
... The BD Macro-Vue RPR (Rapid Plasma ... Tear-drop Tests are nontreponemal testing procedures ... described in A Manual of Tests ... this manual are the most widely ...
Medicine Products: